Protocol Ledger

NCT07250802 · Phase III · RECRUITING

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

Interventional Phase III clinical trial protocol NCT07250802 sponsored by Takeda in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-12-04 Enrollment: 110 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07250802
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)110 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07250802
Protocol FieldVerified Registry Value
NCT IdentifierNCT07250802
Consolidated Lead SponsorTakeda
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment110 participants (ESTIMATED)
Registered Start Date2025-12-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07250802
Hospital Research SiteLocationSite Profile
Medical University of South CarolinaCharleston, SCOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI